Edition:
United States

Profile: Jazz Pharmaceuticals PLC (JAZZ.O)

JAZZ.O on Nasdaq

149.24USD
3:45pm EDT
Change (% chg)

$1.35 (+0.91%)
Prev Close
$147.89
Open
$147.63
Day's High
$150.63
Day's Low
$146.96
Volume
292,122
Avg. Vol
458,603
52-wk High
$163.75
52-wk Low
$95.80

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Company Address

Jazz Pharmaceuticals PLC

Fifth Fl
Waterloo Exchange, Waterloo Road
DUBLIN     4
P: +3531.6347800
F: +3531.6347850

Company Web Links